Qiming Venture Partners

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.

Beijing Health Biotech Co. Ltd. develops diagnostic and therapeutic products for diagnosis, treatment, and monitoring of Alzheimer's disease. The company offers diagnostic and therapeutic products, such as vitamins detection, Alzheimer's disease detection and treatment, prostate AA detection, ceramides test, therapeutic drug monitoring, and screening of neonatal genetic metabolic diseases for Alzheimer's disease, cardiovascular disease, urinary disease, genetic metabolic disease, therapeutic drug monitoring, metabolite detection, steroid hormone detection, trace element quantitative detection, vitamin family detection, and microbiological identification. It also offers clinical testing and research services. The company was founded in 2016 and is based in Beijing, China.

Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on the research and development of innovative therapeutics. The company is actively developing AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with non-small cell lung cancer who have epidermal growth factor receptor (EGFR) mutations and central nervous system metastases. Alpha Biopharma collaborates with prominent domestic and international pharmaceutical companies to enhance the reliability of its product development. The company employs a strong scientific consulting and management team to optimize its drug development strategies, emphasizing a comprehensive approach that includes research, market positioning, and intellectual property protection. Additionally, Alpha Biopharma partners with top contract research organizations, contract manufacturing organizations, hospitals, and institutes to ensure efficient and organized program implementation, supported by a robust project management system.

Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010 and headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris focuses on innovative therapies within the oncology sector and is dedicated to combating the challenges posed by drug-resistant pathogens.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Genor BioPharma Co., Ltd., a biopharmaceutical company, develops and commercializes therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. It is developing two categories of mAb drugs, such as biosimilars and new molecular entities. The company develops products in the areas of cancer, autoimmune disease, and metabolic diseases. Genor BioPharma Co., Ltd. has a strategic collaboration with Ascentage Pharma. The company was founded in 2007 and is based in Shanghai, China. Genor BioPharma Co., Ltd. is a former subsidiary of Walvax Biotechnology Co.,Ltd.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on the research and development of innovative therapeutics. The company is actively developing AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with non-small cell lung cancer who have epidermal growth factor receptor (EGFR) mutations and central nervous system metastases. Alpha Biopharma collaborates with prominent domestic and international pharmaceutical companies to enhance the reliability of its product development. The company employs a strong scientific consulting and management team to optimize its drug development strategies, emphasizing a comprehensive approach that includes research, market positioning, and intellectual property protection. Additionally, Alpha Biopharma partners with top contract research organizations, contract manufacturing organizations, hospitals, and institutes to ensure efficient and organized program implementation, supported by a robust project management system.

Frontage Laboratories is a contract research organization that offers a comprehensive range of research, analytical, and development services to pharmaceutical, biotechnology, and agrochemical companies. The firm specializes in drug discovery and development, providing services in areas such as drug metabolism, pharmacokinetics, safety and toxicology, bioanalytical testing, and chemistry, manufacturing, and controls. Additionally, Frontage supports clinical studies through early-stage clinical services and biometrics. The company serves clients globally, with operations in the United States, Canada, China, Europe, India, Japan, Korea, Israel, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Laboratories is a subsidiary of Hong Kong Tigermed Co., Limited.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is an integrated pharmaceutical group based in Beijing, China, with an additional office in Haikou. Established in 2005, the company specializes in the development and production of both generic and patented therapies, as well as diagnostic agents. Sinotau offers a diverse range of products, including radiopharmaceuticals and biopharmaceuticals, and manufactures various forms of medications such as tablets, capsules, and granules for conditions affecting the cardiovascular, digestive, and respiratory systems, among others. The company's expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations is supported by advanced monoclonal antibody technologies, aiming to serve the biotechnology industry effectively.

ZappRx, Inc. is a digital health company based in Boston, Massachusetts, focused on modernizing the management of specialty medications. Its cloud-based prescription and prior authorization platform enhances efficiency for healthcare providers, specialty pharmacies, and biopharma companies by streamlining the ordering process for specialty drugs. The platform facilitates secure, collaborative interactions among providers, pharmacists, and payers, significantly reducing reliance on traditional communication methods like faxes and phone calls. ZappRx's services are particularly utilized in pulmonary, cardiology, and gastroenterology fields. The company was incorporated in 2012 and, as of June 2019, operates as a subsidiary of Allscripts Healthcare Solutions, Inc.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

Anssure Pharma is a pharma for transdermal patch.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Shenogen Pharma Group is a drug discovery and development company.

dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Shenogen Pharma Group is a drug discovery and development company.

MedSci provides strategies, solutions and services to pharmaceutical, biotech and medical device organization and the consumer healthcare industry

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.

Shenogen Pharma Group is a drug discovery and development company.

Shenogen Pharma Group is a drug discovery and development company.

Gan & Lee Pharmaceutical, Ltd., a biopharmaceutical company, engages in the research, development, production, and commercialization of biosynthetic human insulin and analogues primarily in China. Its products include Basalin, an insulin glargine injection; and Prandilin, an insulin lispro injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceutical, Ltd. in April 2005. Gan & Lee Pharmaceutical, Ltd. was founded in 1998 and is headquartered in Beijing, China.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Gan & Lee Pharmaceutical, Ltd., a biopharmaceutical company, engages in the research, development, production, and commercialization of biosynthetic human insulin and analogues primarily in China. Its products include Basalin, an insulin glargine injection; and Prandilin, an insulin lispro injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceutical, Ltd. in April 2005. Gan & Lee Pharmaceutical, Ltd. was founded in 1998 and is headquartered in Beijing, China.

Gan & Lee Pharmaceutical, Ltd., a biopharmaceutical company, engages in the research, development, production, and commercialization of biosynthetic human insulin and analogues primarily in China. Its products include Basalin, an insulin glargine injection; and Prandilin, an insulin lispro injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceutical, Ltd. in April 2005. Gan & Lee Pharmaceutical, Ltd. was founded in 1998 and is headquartered in Beijing, China.

CITIC Pharmaceutical Co., Ltd. (中信医药) is a pharmaceutical service provider that supplies medicine and related consumables to hospitals. It is a large pharmaceutical operation enterprise integrating medicines supply to hospitals, cross-regional commercial distribution, vaccine sale, medical instruments and consumables sale, and medicine retailing service. In recent years, it has become a pharmaceutical service provider in the supply chain with multiple customized integration service. CITIC Pharmaceutical, which is a subsidiary of CITIC Group, was transformed to a joint venture in 2007. It is invested by China Health System whose holding company is Bioveda China fund and CITIC Investment Holdings Ltd.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.

Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel. Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in China selling pharmaceutical products into US local market. Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology.